Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
|Articles|August 21, 2006
Developing an antimicrobial strategy to combat resistance
As antimicrobial resistance continues to increase inexorably, the good news is that so far there are very few clinical situations for which there are no therapeutic options, said Robert Moellering Jr., M.D., researcher at Harvard Medical School. "But we are getting very, very close," he warned.
Advertisement
Advertisement
Related to this article
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
2
American Pharmacists Month: Technology’s Role in Expanding Pharmacist Scope
3
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
4
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
5